Drug
Fenebrutinib clinical trials
Also written GDC-0853 and RO7010939.
- studies test it
- 17
- open now
- 1
- in phase 3
- 3
- first study started
- 2013
Keep track of what changes. Save the fenebrutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
17 studies that test it; most in 2017 (5)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 8
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Often tested with
Tested in the same studies.
Methotrexate (1) · Midazolam (1) · Rosuvastatin (1) · Simvastatin (1) · Itraconazole (1) · Rabeprazole (1)
Studies
Open first, then newest update. How each study uses fenebrutinib is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)RecruitingPhase 2Hoffmann-La RocheNCT07161258Written as Fenebrutinib
- A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 2Hoffmann-La RocheNCT05119569Written as Fenebrutinib
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04586010Written as Fenebrutinib
- Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04586023Written as Fenebrutinib
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisActive, not recruitingPhase 3Hoffmann-La RocheNCT04544449Written as Fenebrutinib
- A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusCompletedPhase 2Genentech, Inc.NCT02908100Written as GDC-0853
- A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.CompletedPhase 1Genentech, Inc.NCT01991184Written as GDC-0853
- An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusTerminatedPhase 2Genentech, Inc.NCT03407482Written as GDC-0853
- A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).CompletedPhase 2Genentech, Inc.NCT03137069Written as GDC-0853
- A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) StudyTerminatedPhase 2Genentech, Inc.NCT03693625Written as GDC-0853
- A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350CompletedPhase 2Genentech, Inc.NCT02983227Written as GDC-0853
- Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)CompletedPhase 2Genentech, Inc.NCT02833350Written as GDC-0853
- Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy SubjectsCompletedPhase 1Genentech, Inc.NCT02699710Written as GDC-0853
- A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and SimvastatinCompletedPhase 1Genentech, Inc.NCT03174041Written as GDC-0853
- A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT03290703Written as GDC-0853
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian ParticipantsCompletedPhase 1Hoffmann-La RocheNCT03188783Written as GDC-0853
- Study Investigating a Single Oral Dose of Fenebrutinib in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT03596632Written as Fenebrutinib
Codes
What other systems call fenebrutinib · ClinicalTrials.gg INT000676
- MeSH (NLM) C000619415fenebrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) E9L2885WULFENEBRUTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q23304817fenebrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116844FenebrutinibOne source FDA
- DrugBank DB14785One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619415 | fenebrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | E9L2885WUL | FENEBRUTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q23304817 | fenebrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116844 | Fenebrutinib | One source FDA |
| DrugBank | DB14785 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.